U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 50

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with application dated September 22, 2020,	4. Expiration Date: February 28, 2026
1. Henry Ford Wyandotte Hospital 2. 2333 Biddle Ave. Wyandotte, MI 48192	3. License No.: 21-12930-01 is amended in its entirety to read as follows:	5. Docket No.: 030-02140 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 5 millicuries total	D. For use in in-vitro studies.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-12930-01	Docket or Reference No.: 030-02140
	Amendment No. 50	

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at:
    A. Licensed material may be used at the licensee's facilities located at 2333 Biddle Ave., Wyandotte, Michigan.
    B. Licensed material listed in Subitem No. 6.B. may be used at the licensee's facilities located at Henry Ford Health Center - Brownstown, 23050 West Rd., Brownstown Township, Michigan.

11. The Radiation Safety Officer (RSO) for this license is Alan M. Jackson, M.S., CHP.

12. The Associate Radiation Safety Officer (ARSO) for this license is Mayur V. Vaya, B.S., CNMT, NMTCB(RS), R.T.(N), for 10 CFR 35.100, 10 CFR 35.200, and 10 CFR 35.300.

13. Licensed material shall only be used by, or under the supervision of:

    A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

    B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
Kevin J. Berlin, D.O.	10 CFR 35.200
Vito A. Casano, M.D.	10 CFR 35.100,10 CFR 35.200
Charles Terrell Cash, III, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Donald J. Conn, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
John H. Finger, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Monica A. Gerst, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-12930-01	Docket or Reference No.: 030-02140
	Amendment No. 50	

Authorized User (M.D.,D.O.,etc.)	Material and Use
Jessica Marie Kaniowski, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Dong Hyuck Kim, M.D.	10 CFR 31.11,10 CFR 35.100,10 CFR 35.200
James J. Kochkodan, M.D.	10 CFR 31.11,10 CFR 35.100,10 CFR 35.200
Ronald Joseph Meade, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Gregory D. Olson, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Rob Allen Reed, M.D.	10 CFR 35.100,10 CFR 35.200
David James Rossow, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Sophia Roumanis, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Gehring T. Sauter, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Mitchell Scheer, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Michael F. Zydeck, M.D.	10 CFR 35.100,10 CFR 35.200

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-12930-01	Docket or Reference No.: 030-02140
	Amendment No. 50	

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 23, 2015 (ML15275A432)
B. Letter dated January 25, 2016 (ML16025A212)
C. Letter dated November 20, 2017 (ML17325A839)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 25, 2021

By: Colleen Carol Casey
Colleen Carol Casey
Region 3